Pharmacokinetics and safety of bilastine in children aged 6 to 11 years with allergic rhinoconjunctivitis or chronic urticaria
information for practice - Journal Article Abstracts,
Abstract Bilastine, a second-generation antihistamine, is approved in Europe for the treatment of allergic rhinoconjunctivitis…